Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

BACKGROUND: Modulation of the PD-1/PD-L1 axis through antagonist antibodies that block either receptor or ligand has been shown to reinvigorate the function of tumor-specific T cells and unleash potent anti-tumor immunity, leading to durable objective responses in a subset of patients across multipl... View More